All In Biotech

Drug Trial Radar · NCT02487550

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

Last checked: Nov 19, 2026Latest source record: Jul 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Aug 2015

Primary completion

Jul 2028

Study completion Jul 2030

Sponsor

Lead sponsor
The First People's Hospital of ChangzhouAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.

Conditions

  • Renal Neoplasma

Interventions

  • DC-CIKBiological

    Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.

  • IL-2/IFN-αBiological

    Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free timeTime frame: 3 months
  2. Overall-survival timeTime frame: 3 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.